Aditxt Faces New Nasdaq Delisting Threat Over Negative Equity, Compounding Prior Bid Price Issue
Summary
Aditxt, Inc. received an additional Nasdaq delisting notice due to its negative stockholders' equity, further jeopardizing its listing status ahead of a scheduled hearing for a prior minimum bid price deficiency.
Key Events
-
New Delisting Notice Received
Aditxt received a letter from Nasdaq on May 27, 2026, notifying the company of non-compliance with the minimum stockholders' equity requirement of $2.5 million.
-
Significant Financial Deficiency
The company reported stockholders' equity of negative $35.17 million as of March 31, 2026, far below the Nasdaq requirement. It also fails alternative listing standards for market value of listed securities and net income.
-
Aggravated Delisting Risk
This new deficiency serves as an additional basis for delisting and will be considered by the Nasdaq Hearings Panel at the previously scheduled hearing on June 11, 2026, which was set to address the prior minimum bid price non-compliance.
-
Potential Third Deficiency Identified
The company has also determined it is not in compliance with the $1 million Market Value of Publicly Held Shares requirement, which may also be considered by the Panel.
Analysis
This filing reveals a new and significant reason for Aditxt's potential delisting from Nasdaq: a severe deficiency in stockholders' equity, which stands at a negative $35.17 million against a $2.5 million requirement. This adds to an existing delisting notice for failing the minimum bid price requirement and a potential third deficiency for Market Value of Publicly Held Shares. The accumulation of these issues significantly increases the likelihood of delisting, which would severely impair the company's ability to raise capital and maintain liquidity, raising substantial doubt about its ability to continue as a going concern.
At the time of this filing, ADTX was trading at $0.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $95.6K. The 52-week trading range was $0.11 to $53,450.61. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.